The inactivity on the MB is a direct reflection on GALT. You need look no further than the volume. This about as thinly traded a stock as there is. Back in October, GALT told us they would begin dosing patients in late January of 2013. Here we are in the middle of July & still no announcement of IF or WHEN GALT will ever begin to dose patients. IMO, a wise investor will sit on the sidelines and wait until some verifiable CLINICAL results are released. Obviously, there can't be any CLINICAL results until then BEGIN dosing patients........now do you understand why this MB is DEAD?
You are exaggerating the degree to which they have delayed the dosing - they said in the Nov 2012 earnings release that they planned on filing the IND by January (which they did) and that they would initiate the trial "in early 2013". They got the IND approval back from the FDA in early March, at which point they said dosing would begin in May. Obviously, they are a bit optimistic with their clinical timeline predictions, which is common for small, inexperienced biotechs, but I don't think there is anything sinister going on here?
The above post is very apropos. GALT, the Board of GALT have maneuvered enough investors to manage the salaries and bonuses for the present fiscal year. When funds start running low, the propaganda machine will be back in motion. Dr. Traber and his cronies will be singing the praises of their wonder drug and designing strategies to enroll investors to part with their HARD earned monies. At that time, this message board will once again be very active.
Want to go to a different board? Make a suggestion and I'll be there. I don't post here anymore due to Doolittle and his side kick. I suggest we migrate to GILD and post there based on todays press release it is relevant - thoughts?
"I suggest we migrate to GILD and post there based on todays press release it is relevant - thoughts?"
I think the Gilead regulars might have something to say about it. It took a lot of nosing around the website to find the disclaimer, but the article was a paid for advertisement intended to have the look and feel of independent research. GALT has made steps toward being a legitimate biotech opportunity than can be taken seriously, and then they revert to rank self promotion and hucksterism.